

Erdafitinib THOR/BLC3001 cohort 1

**PRELIMINARY SCORE**

**CURATIVE**



**NON-CURATIVE**



**ADJUSTMENTS**

**Quality of life**



QoL data pending



**Serious and disabling adverse effects**




**Other adjustments**



Erdafitinib THOR/BLC3001 cohort 1

**FINAL SCORE**

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Genitourinary Cancers

Therapeutic Indication: For adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, whose disease has progressed on or after at least one line of prior systemic therapy.

Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.

Experimental Arm: Erdafitinib

Control Arm: ChT (docetaxel or vinflunine)



